Nurix Therapeutics (NASDAQ:NRIX) Stock: Insider Julia Gregory Sells 22,583 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Director Julia Gregory sold 22,583 shares of the stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the transaction, the director directly owned 10,750 shares in the company, valued at approximately $251,550. This represents a 67.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nurix Therapeutics Stock Up 5.4%

NASDAQ NRIX opened at $24.95 on Friday. The stock’s 50-day simple moving average is $25.13 and its two-hundred day simple moving average is $21.13. Nurix Therapeutics, Inc. has a twelve month low of $9.71 and a twelve month high of $28.23. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 10.80 and a beta of 1.82.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The firm had revenue of $673.06 million during the quarter, compared to analyst estimates of $24.35 million. On average, equities analysts expect that Nurix Therapeutics, Inc. will post 0.85 earnings per share for the current fiscal year.

Nurix Therapeutics News Roundup

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst maintained a “Strong Buy” rating, citing promising earlier-stage data, potential accelerated approval and multiple development opportunities. Bexobrutideg clinical analysis
• Positive Sentiment: Analyst sentiment remains broadly bullish. Baird raised its price target to $36 and maintained an “Outperform” rating, while Needham reiterated “Buy” with a $34 target. The consensus target is approximately $34.64, above recent trading levels. Nurix analyst ratings
• Neutral Sentiment: Nurix’s quarterly results significantly exceeded estimates, with earnings of $4.73 per share versus a projected loss of $0.60 and revenue of $673.06 million versus a $24.35 million consensus estimate. However, the earnings reaction was tempered by higher operating expenses as the company continues investing in its pipeline. Nurix quarterly earnings
• Negative Sentiment: Truist reduced its price target for Nurix while retaining a “Buy” rating, signaling more cautious near-term expectations despite confidence in the company’s longer-term prospects. Truist price target update
• Negative Sentiment: Director Julia Gregory sold 22,583 shares for about $528,000, reducing her direct ownership by 67.75%. Separately, insider Gwenn Hansen sold 1,452 shares for $36,300 under a pre-arranged Rule 10b5-1 plan. While planned sales may reflect diversification or personal financial needs, the transactions can weigh on investor sentiment. Nurix insider sale filing

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. General Atlantic L.P. bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $92,899,000. Trails Edge Capital Partners LP purchased a new stake in Nurix Therapeutics during the 2nd quarter valued at about $38,166,318. Bank of New York Mellon Corp purchased a new position in shares of Nurix Therapeutics in the second quarter worth $6,614,000. Man Group plc purchased a new position in shares of Nurix Therapeutics in the second quarter valued at about $2,076,000. Finally, Baker BROS. Advisors LP lifted its holdings in Nurix Therapeutics by 20.0% in the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock worth $88,373,000 after buying an additional 776,431 shares during the period.

Analysts Set New Price Targets

A number of research firms recently weighed in on NRIX. Wall Street Zen upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. HC Wainwright upped their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Mizuho increased their price target on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Morgan Stanley increased their price target on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Finally, UBS Group lifted their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.64.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.